Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant what is the number needed to treat, number needed to harm and likelihood to be helped or harmed
International Journal of Clinical Practice,  Evidence Based Medicine  Clinical Article

Citrome L – Vilazodone represents another option for the treatment of major depressive disorder (MDD). Vilazodone appears to have a favourable weight–gain profile based on short–term studies. Sexual side–effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long–term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment.

Methods
  • The pivotal registration trials were accessed by querying , and for the search term `vilazodone'.
  • Product labeling provided additional information.
  • All available clinical reports of studies were identified.
  • Descriptions of the principal results and calculation of number needed to treat (NNT) and number needed to harm (NNH) for relevant dichotomous outcomes were extracted from the available study reports and other sources of information.

Results
  • Vilazodone is a specific serotonin reuptake inhibitor and serotonin 5HT1A receptor partial agonist.
  • In needs to be administered with food to ensure adequate bioavailability.
  • Approval for the treatment of MDD was based on a clinical development programme that included two 8–week placebo–controlled randomised clinical trials in outpatients with MDD where vilazodone was titrated to a target dose of 40mg/d over the first 2weeks.
  • Both trials evidenced efficacy for vilazodone as measured by the Montgomery Asberg Depression Rating Scale.
  • NNT for response vs. placebo was 8 (95% CI 6–16) and for remission was 14 (95% CI 8–55). NNH vs. placebo for discontinuation because of an adverse event (AE) was 27 (95% CI 15–104).
  • The most commonly encountered AEs (incidence ≥5% and at least twice the rate of placebo) were diarrhoea, nausea, vomiting and insomnia, with NNH values vs. placebo of 6 (95% CI 5–8), 6 (95% CI 5–8), 30 (95% CI 18–82) and 26 (95% CI 16–78), respectively.
  • NNH vs. placebo for any sexual AE was 12 (95% CI 9–18), but systematically collected data using rating scales of sexual function did not reveal treatment associated effects.
  • Vilazodone was not associated with clinically relevant weight change in the short–term trials.
  • In an open–label 1–year study of vilazodone, mean weight increased by 1.7kg among the observed cases.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 Precautionary labelling of foods for allergen content: Are we ready for a global framework? Full Text World Allergy Organization Journal, May 8, 2014    Free full text    Review Article

2 A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: Sorafenib for second line renal cell cancer Full Text Cost Effectiveness and Resource Allocation, May 5, 2014    Free full text

3 FDA approves Afrezza to treat diabetes Full Text FDA Press Announcements, June 30, 2014    Free full text

4 Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder Annals of Pharmacotherapy, July 25, 2014    Review Article    Clinical Article

5 One injection stops diabetes in its tracks Salk Institute News, July 18, 2014

6 New research indicates statin drugs must be taken properly Michigan State University Health News, July 22, 2014

7 Honey as an effective antimicrobial treatment for chronic wounds Full Text Chronic Wound Care Management and Research, August 21, 2014    Free full text    Review Article

8 Acetaminophen plus ibuprofen versus opioids for treatment of post-tonsillectomy pain in children International Journal of Pediatric Otorhinolaryngology , August 18, 2014    Clinical Article

9 Beta-blockers in heart failure with preserved ejection fraction: A meta-analysis Heart Failure Reviews, July 28, 2014    Evidence Based Medicine    Review Article    Clinical Article

10 New cholesterol guideline: LDL goals take backseat to statins Full Text American Pharmacists Association News, November 15, 2013    Free full text    Clinical Guideline

11 Is the standard dose of amoxicillin-clavulanic acid sufficient? Full Text BMC Pharmacology & Toxicology, August 8, 2014    Free full text    Clinical Article

12 “Worm pill” could ease autoimmune disease symptoms Monash University News, August 11, 2014

13 Efficacy of high-dose versus standard-dose influenza vaccine in older adults New England Journal of Medicine, August 15, 2014    Evidence Based Medicine    Clinical Article

14 Bedtime aspirin may be more beneficial for heart patients Full Text Pharmacy Times, December 2, 2013    Free full text    Clinical Article

15 Eating probiotics regularly may improve your blood pressure American Heart Association News, July 24, 2014

16 Therapeutics Initiative warns of statin side effects The University of British Columbia Health News, May 30, 2014

17 Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications Full Text Journal of Pharmacy and Pharmaceutical Sciences, January 3, 2014    Free full text    Clinical Article

18 Are chromium supplements helpful in lowering blood sugar levels? Full Text EurekAlert!, April 10, 2014    Free full text

19 Statin use and mortality among blacks and whites in the Southeastern US Full Text Clinical Epidemiology, August 11, 2014    Free full text    Clinical Article

20 First drug candidate from NIH program acquired by biopharmaceutical company Full Text NIH News, July 10, 2014    Free full text

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close